Skip to content

Diode Laser Versus Topical Corticosteroids in Management of Oral Ulcers in Behcet's Disease

Active Control,Randomized,Double- Blinded Clinical Trial of BD

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03771768
Acronym
BD
Enrollment
38
Registered
2018-12-11
Start date
2019-05-25
Completion date
2019-05-25
Last updated
2019-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune, Behcet Syndrome

Keywords

Oral ulcers

Brief summary

Laser therapy is increasingly showing promising results in dental field including oral ulcers.This trial will assess the usefulness of Diode Laser compared to corticosteroid on oral ulcers of patients diagnosed with Behcet's disease.

Detailed description

The enrolled patients will be divided randomly into two groups.one group will receive Diode Laser (power:100 milli Watt,wavelength:980 mmm, delivery system:biostimulation probe) and other group will receive topical corticosteroids(Kenacort A Orabase: triamcinolone acetonide 0.1% 5 gram adhesive paste - Dermaphor) four times daily.

Interventions

RADIATIONDiode laser 980nm&100 mWatt

Diode laser 980 nm &100 milli Watt.

DRUGTriamcinolone Acetonide

0.1 &5gm paste 4 times/day

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Caregiver, Investigator)

Masking description

Double - blinded trial: Outcome assessor (CS) and Statistician. Participants couldn't be blinded because of the difference in the nature of interventions method of application.

Intervention model description

1:1

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* patients diagnosed with Behcet's Disease according to International Criteria for BD. * patients with active oral ulcers. * patients free from any visible oral lesions other than the oral ulcers of BD. * patients who agreed to take the supplied interventions. * patients who will agree to participate in the study. * patients who will accept to sign the informed consent.

Exclusion criteria

* patients not physically able to participate in survey or clinical oral examination. * patients with organ or life-threatening disease. * patients with history of a severe or chronic medical condition including tuberculosis, hepatitis and human immunodeficiency virus. * patients under immunosuppressive drugs. * patients with organ transplantation.

Design outcomes

Primary

MeasureTime frameDescription
Oral ulcer activity indexOne monthComposite index score (0-10)

Secondary

MeasureTime frameDescription
Oral health - related quality of lifeOne monthOral health impact profile - 14 (OHIP- 14)
Pain associated with oral ulcerOne monthVisual analogue scale (0-10)

Contacts

Primary ContactClair Sobhy Nagieb, MSC
Clair.nadieb@dentistry.cu.edu.eg01222259819
Backup ContactZaki S.Zaki, MSC
drzaki95@yahoo.com01224045116

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026